Oleuropein Reduces Prdx1 Expression, Cell Proliferation and Viability in K562 Human Leukemia Cells

Sophia R. Fagan1, Natalie M. Fulco2, Dr. Shelley A. Phelan PhD3*

1Research Associate, Pediatric Genomics Discovery Program, Yale Medicine, U.S.A
2Fairfield University, Fairfield CT, U.S.A
3Professor, Department of Biology, Fairfield University, Fairfield CT, U.S.A

*Corresponding Author: Dr. Shelley A. Phelan, Professor, Department of Biology, Fairfield University, Fairfield CT, U.S.A., Email: sphelan@fairfield.edu

Abstract: Oleuropein is one of the two main phenolic compounds derived from olive leaves. Numerous studies have found that the polyphenols contained in olive leaves possess strong antioxidant properties, and increase apoptosis in many types of cancer cells, suggesting its possible efficacy as an anti-cancer treatment. The purpose of this study was to examine the effects of oleuropein extract on cell growth and viability of the K562 human leukemia cell line. It was first demonstrated that cells treated with 200 or 400 μg/mL oleuropein exhibited a significant reduction in cell number and viability after four days, as compared to ethanol-treated controls. Cells treated with 200 μg/mL oleuropein showed approximately 90% reduction in cell density and viability after four days of treatment, while the 400 μg/mL concentration resulted in 100% toxicity by the fourth day. It was also found that a two-fold elevation in LDH release within 24 hours of treatment with 200 μg/mL oleuropein, confirming cytotoxicity. Examination of caspase-1 activity revealed an increase in apoptosis within 24 hours. To begin to explore a mechanism of action, we examined the effect of oleuropein on expression of the Peroxiredoxin (Prdx) family of antioxidant proteins. A concentration of 200 μg/mL oleuropein reduced Prdx1 expression by about 50% after eight and twenty-four hours. This study reveals new data on the specific effects of oleuropein on K562 cells, and the regulation of Prdx1 as a possible mechanism of action. Together with previous reports, this research provides further insight into our understanding of natural products as anti-cancer agents.

Keywords: Oleuropein, K562 human leukemia, natural anti-cancer agents, olive leaves, Peroxiredoxin expression

1. INTRODUCTION

Olive leaves have been used in Mediterranean cultures for centuries because they are believed to possess notable health benefits. Olive leaves are largely harvested in Asia, Arabian Peninsula, Indian subcontinent, and Mediterranean regions of the world (20). Studies have shown that olive leaves have many known useful pharmacological effects, and they have ultimately been used to treat a wide variety of ailments (16). There are many reports that Mediterranean people have created olive leaf tea, powder, or extract as a natural remedy to various diseases. Historically, the most traditional uses of olive leaves have been; oral ingestion for stomach and intestinal diseases, chewed as a mouth cleanser, dried and orally ingested for diarrhea and urinary tract infections, added to hot water to treat high blood pressure as well as encourage urination, and the addition of an extraction of the dried plant to hot water in order to treat bronchial asthma (20). Olive leaf extract contains higher levels of polyphenols than extra virgin olive oil. Polyphenols are an aromatic structure with varying number of hydroxyl groups (3). These aromatic structures then attach together in various orientations to create distinct polyphenols (3). The total polyphenol content found in olive tree leaves is 2.058 mg per 100 g (20). Olive trees are predominantly grown in the Mediterranean region where they face periods of extended sunlight and pathogenic insect attack. As a response to these conditions, olive trees create a high volume of polyphenols which are stored in the leaves of the trees.

Polyphenols have been shown to lower glucose levels in the blood stream, lower cholesterol levels, and have cardio protective properties (16). The polyphenols from olive leaves have proven to be anti-inflammatory and act as
antioxidants through protecting DNA by scavenging free radicals and removing potentially harmful oxidizing agents (3). These phenolic compounds from olive leaves are of growing interest in the cancer-research field due to the anti-proliferative and apoptosis inducing properties that they have on various cancer cell lines (16). Olive leaves have been demonstrated to have the highest antioxidant content compared to the rest of the tree (20).

Oleuropein is a naturally occurring extract that comes from olive leaves and is part of the oleuropeosides phenolic compound group of olive leaf phenolic components. Oleuropein is the most abundant phenol and accounts for 6-9% of dry matter in the olive leaf (21). It is present in the highest amounts in the unprocessed olive fruit and leaves. In aqueous extracts from the olive leaves it is the major compound, accounting for approximately 73% of the total compounds identified. Oleuropein itself is an antioxidant, which inhibits oxidation that can cause free radical accumulation leading to damaged proteins, DNA, and cell membranes in the cells. Additionally, oleuropein inhibits the oxidation of low density lipoproteins in cells (21). When there is an increase of antioxidants there will be an overall reduction in chronic diseases (20). It is believed that the ability of oleuropein to prevent the formation of free radicals is due to its ability to form several bonds with metal ions such as Cu and Fe. This in turn catalyzes the free radical generation reactions and inhibits various inflammatory enzymes such as lipoxygenases. This is successfully done without affecting the cyclooxygenase pathway which forms prostanoids. Oleuropein has also been shown to be a scavenger superoxide anion and possesses the ability to inhibit the respiratory burst of neutrophils and hypochlorous acid-derived radicals. It also is known to scavenge hydroxyl radicals as well as 1,1-diphenyl-2-picrylhydrazyl radicals (20). Previous studies have examined the effect of oleuropein treatments on cell proliferation and apoptotic induction of various cancer cell lines. Oleuropein has been found to be cytotoxic to human osteosarcoma cancer cells by inhibiting their ability to proliferate under the extracts conditions (13). Further studies have found that oleuropein reduced cell viability and induced thiol group modifications in two different prostate cancer cell lines; LNCaP and DU145 (1). Yet another showed that oleuropein inhibited cell proliferation and induced apoptosis in MCF-7 breast cancer cells through the mitochondrial pathway (6). Yet another study tested the cytotoxic action of oleuropein by itself or in conjunction with chemotherapeutics on A375 human melanoma cells. It was found that oleuropein was able to stimulate an apoptotic response in the cell at a dose of 500µM. This dose of oleuropein affected cell proliferation and induced the down regulation of the pAKT/pS6 pathway (19). Together, there is mounting evidence that the oleuropein extract can successfully be used in a wide variety of cancer cell lines to affect cell proliferation and induce cell death.

Peroxiredoxins (Prdxs) are a large family of proteins that is highly conserved in all cells. The main role of Prdxs is to regulate cellular and lipid peroxide levels that accumulate in the cell by way of rapidly detoxifying hydrogen peroxide, organic hydroperoxides, and peroxynitrite (14). Members of the peroxiredoxin family share a thioredoxin fold and contain a highly-reactive active site peroxidatic cysteine, which functions to reduce peroxide substrates (5, 18). Peroxiredoxin-mediated regulation of H2O2 levels facilitates their role in cell proliferation, differentiation, and apoptotic pathways (11, 14). Much research has demonstrated that peroxiredoxins can function as tumor suppressors, and peroxiredoxin levels have been shown to be up regulated in various cancers (4,8,10,15,17). The present study sought to investigate the effect of oleuropein on growth and viability in the K562 human leukemia cell line, and also investigate whether oleuropein would regulate the Peroxiredoxin family of antioxidant proteins.

2. MATERIALS AND METHODS

2.1. Preparation of Oleuropein

Oleuropein was ordered from Sigma-Aldrich at >98% purity. Catalog #: 12247. The oleuropein extract was dissolved in 70% ethanol to create a 100 mg/mL stock solution. This stock solution was stored at -20°C and protected from light.

2.2. K562 Cells

The human leukemia K562 cell line was purchased from ATCC. The cells were culture in media comprised of 90% Iscove’s Modified Dulbecco’s Medium (IMDM) catalog #SH30228.01 purchased from GE Life Sciences and 10% Fetal bovine serum (FBS) ATCC 30-2020. Cells were grown and maintained at 37 °C in a humidified 5% CO2 incubator.
2.3. Analysis of Cell Growth and Viability

In order to analyze the effect of oleuropein treatment on cell growth and viability, cells were plated at a density of $5\times10^4$ cells/mL in a 96-well plate. In replicates of six, cells were treated with 0.14% ethanol, 0.28% ethanol, 100 μg/mL oleuropein, 200 μg/mL oleuropein, or 400 μg/mL oleuropein. (Ethanol controls included equivalent amounts of 70% ethanol to the corresponding oleuropein treatments as vehicle controls.) Each day over a four-day period, cells in each well were counted using a hemocytometer and a Trypan Blue Exclusion Assay to determine viable cells. Statistical analysis of data were carried out using a two-tailed student’s t-test.

2.4. Measurement of Cytotoxicity

To examine the effect of the cytotoxicity of the oleuropein compound on the K562 cells a Lactate Dehydrogenase (LDH) Assay was used. This assay is a colorimetric method for quantifying cellular cytotoxicity by measuring the release of LDH into cell culture media when the plasma membrane is damaged. K562 cells were plated at a density of $5\times10^5$ cells/mL. Replicates of six were performed for each of untreated, 0.14% ethanol, and 200 μg/mL oleuropein and media levels of LDH levels were measured daily over a 72 hour period by measuring formazan absorbancy at 490 nm. Statistical analysis of data were carried out using a two-tailed student’s t-test.

2.5. Measurement of Apoptosis

To examine the effect of oleuropein treatment on cell apoptosis of the K562 cell line, a Caspase-1-ICE Assay was used. K562 cells were plated at a density of $5\times10^5$ cells/mL. Replicates of four were performed for untreated and 200 μg/mL oleuropein treated cells. The activation of caspase-1 was assessed by measuring the enzymatic product absorbance at 400 nm after 24 and 48 hours. Statistical analysis of data were carried out using a two-tailed student’s t-test.

2.6. Measurement of Peroxiredoxin Expression

Cells were plated at a density of $5.0\times10^5$ cells/mL in a 24-well plate. In replicates of three, cells were untreated or treated with 200 μg/mL oleuropein for 8 or 24 hours. Protein was extracted using the Mammalian Protein Extraction Reagent (MPER). Proteins were quantified using Coomassie Plus, and equivalent amounts of total protein were separated by SDS-PAGE gel electrophoresis followed by transfer to a PVDF membrane. Western blotting was used to analyze protein expression of Peroxiredoxins using primary antibodies from Abcam: Prdx1 (AB58252), Prdx2 (AB109367), Prdx3 (AB16761), Prdx4 (AB59542), and Prdx6 (AB16947). An antibody to Gapdh (Sigma-G9545) was used as a control. Alkaline-phosphatase conjugated secondaries were used, followed by the CDP-Star reagent. Chemiluminescence was detected and images captured using the GBOX system. SynGene Gene tools software was used for band quantification.

3. RESULTS

![Figure 1A](image_url)
Figure 1. **Effect of Oleuropein on K562 Cell Density and Viability.** K562 cells were treated with varying concentrations of oleuropein (or ethanol controls) for four days, and viable cell density and % viability were measured using trypan blue exclusion. **(A)** Average viable cell density; **(B)** Percent viability. Averages are shown (+/- stdev). A student’s t-test was used for statistical analysis.

As shown in Figure 1, after four days of oleuropein treatment, there was a marked decrease in cell density for cells treated with 200 μg/mL and 400μg/mL oleuropein, as compared to ethanol control-treated cells (Fig 1A). In contrast, a much more modest, yet significant, reduction was observed with a concentration of 100μg/mL. Upon investigation of cell viability in these cultures, we found a significant reduction in cell viability with all three concentrations of oleuropein (Fig 1B).

The reduction in viability for the 100 μg/ml concentration was very slight, dropping to only 90% after four days, while the higher concentrations resulted in a marked decrease in viability to around 10%.

The time course of the observed effect was then investigated by measuring cell density and viability daily over a four-day period. While controls were noticeably growing after two days, there was almost complete growth inhibition as early as two days with both concentrations of oleuropein treatment (Fig 2A). Cell number did not increase in either treatment for the remaining two days of the experiment. Likewise, a significant reduction in viability was observed as early as one day after treatment in both concentrations of oleuropein (Fig 2B).
Oleuropein Reduces Prdx1 Expression, Cell Proliferation and Viability in K562 Human Leukemia Cells

Figure 2B

Figure 2. Kinetics of the Effect of Oleuropein on K562 Cell Density and Viability. K562 cells were treated with 200 μg/mL and 400 μg/mL concentrations of oleuropein (or ethanol controls) for four days, and viable cell density and % viability were measured daily using trypan blue exclusion. (A) Average viable cell density; (B) Percent viability. Averages are shown (+/- stdev). A student’s t-test was used for statistical analysis.

The magnitude of the reduction differed, with the lower concentration exhibiting nearly 90% viability after one day, while the higher concentration dropped to about 50% viability after one day. Viability dropped to under 50% by day two in both concentrations, and further dropped to approximately 10% viability by days three and four.

To investigate whether oleuropein was inducing cytotoxicity in these cells, the release of lactate dehydrogenase was measured in a standard LDH release assay. It was decided to use the lower concentration of oleuropein (200 μg/ml) for the remaining experiments. As shown in Figure 3, LDH release was significant as early as one day after treatment. Released LDH levels continued to rise after days 2 and 3, suggesting further toxicity. As shown, there was no difference between baseline levels untreated and ethanol-treated cells throughout the three-day experiment. To further investigate the mechanism of cell death, apoptosis was examined using a caspase-1 assay.

Figure 3. Effect of oleuropein on K562 cytotoxicity. K562 cells were treated with 200 μg/mL oleuropein (or ethanol control) for 72 hours, and cytotoxicity was measured by an LDH release assay. Average absorbance related to released LDH levels is shown (+/- stdev). A student’s t-test was used for statistical analysis.
As shown in Figure 4, only baseline levels of caspase-1 were seen after one day of oleuropein treatment, comparable to controls. However, a significant increase in caspase-1 activity was observed after 48 hours of treatment.

**Figure 4. Effect of Oleuropein on K562 apoptosis.** K562 cells were treated with 200 μg/mL oleuropein (or ethanol control) for 72 hours, and apoptosis was measured using a Caspase-1 activity assay. Average absorbance related to caspase-1 activity is shown (+/- stddev). A student’s t-test was used for statistical analysis.

Given its demonstrated effects on K562 cells, it was decided to determine if oleuropein treatment affected levels of peroxiredoxin antioxidant proteins in these cells. Western blotting was used to measure the levels of five of the six peroxiredoxin proteins after oleuropein treatment. As shown in Figure 5, there was a significant reduction of Peroxiredoxin 1 by 8 hours after treatment, and levels remained lower after 24 hours (Fig 5A). Quantification of the Prdx1 levels showed a nearly 50% reduction in Prdx1 at both time points. In contrast, expression of Prdxs 2, 3, 4, and 6 did not change when comparing untreated, 8 hour treatment, and 24 hour treatments.

**Figure 5A**
Oleuropein is thought to be a promising anti-cancer agent due to its powerful antioxidant and anti-angiogenic properties. This study aimed to determine the effect of oleuropein on K562 human leukemia cells, to understand more about its mechanism of action and ability to regulate antioxidant expression. The results confirmed that oleuropein significantly decreased cell growth and viability, which correlated with an increase in cytotoxicity and apoptosis in treated cells. These data are consistent with previous reports (21).

These data suggest that oleuropein is cytotoxic to K562 cells, and that these cells are dying, at least in part, by apoptosis. While this may explain the significant reduction in cell density we observed in our studies, it is possible that oleuropein additionally has a growth-inhibitory property. There was a clear dose-response to oleuropein in these cells, suggesting that the range of concentrations used are not above a threshold for maximum toxicity. Further examination of the dose-effect of oleuropein will be important so the most physiologically relevant (yet effective) concentrations can be used in further studies.

The ability of oleuropein to down-regulate Prdx1 is interesting. Previous studies from the Phelan lab and others have shown that many cancer cells up-regulate peroxiredoxins, likely as a mechanism to withstand and combat increased oxidative stress (12, 22). It is possible that the reduction of Prdx1 in response to oleuropein may assist in mediating its cytotoxic effects in these cells. Prdx1 is known to be an important antioxidant in blood cells, so this is quite possible, however will require further investigation to confirm.

Continued studies are underway in our lab to examine other signaling and antioxidant pathways that are altered by this treatment, in an effort to further understand the mechanism of action in K562 cells, and the possibility of oleuropein as an anti-cancer treatment.

ACKNOWLEDGEMENTS

This work was supported by funding from Fairfield University College of Arts and Sciences, as well as research support from the Mancini Family, Guillet family, and Femia Science Fund.

REFERENCES


Oleuropein Reduces Prdx1 Expression, Cell Proliferation and Viability in K562 Human Leukemia Cells


